ASX Announcement

23 July 2018

Company Appointment

Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise of the appointment of Ms Nuket Desem as Director of Clinical and Regulatory affairs.

Nuket brings to ANP over 20 years' experience in global regulatory affairs, clinical development and project management obtained through her roles within the pharmaceutical/biotechnology industry, including senior positions in various biotechnology companies. Nuket was also previously employed at Antisense Therapeutics (2004–2010) as the Company's Development Director where part of Nuket's responsibility was the management of ANP's clinical trial programs. Major achievements in this role included the successful conduct and completion of the Company's multinational Phase IIa clinical trial of ATL1102 for the treatment of Multiple Sclerosis.

At Antisense Therapeutics, Nuket will be responsible for developing the Company's global clinical and regulatory strategy for its product pipeline and for execution of the Company's clinical development plans, including the conduct of the Phase II clinical trial of ATL1102 in Duchenne Muscular Dystrophy at the Royal Children's Hospital in Melbourne.

"Nuket brings a depth of experience that will be invaluable in the execution of our product development and regulatory plans," said Mark Diamond, Antisense Therapeutics Managing Director and Chief Executive Officer. "She possesses deep clinical and regulatory expertise with a proven record of developing and executing on such strategies and her experience will be a key to us successfully advancing our products through clinical development. We are delighted to have Nuket back with us at ANP where she will serve on the leadership team".

Nuket joins Antisense Therapeutics from Paranta Biosciences, where she held the position of Director Clinical and Regulatory Affairs. There, she led the clinical and regulatory activities associated with the development of Paranta's recombinant human follistatin protein, PB01, for various indications. Prior to Paranta, Nuket was Senior Manager Development and Regulatory Affairs at Prana Biotechnology.

Earlier, Nuket served as Vice President Clinical and Regulatory Affairs at Spinifex Pharmaceuticals, (now part of Novartis) and was responsible for the management of the regulatory and clinical trial programs of Spinifex Pharmaceuticals' highly selective AT_2 receptor antagonist, EMA401, for the treatment and management of neuropathic pain. In this role, Nuket completed multiple clinical trials including a successful multinational proof of concept study of EMA401 in patients with post-herpetic neuralgia. Spinifex was acquired by Novartis for continued development of EMA401.

Nuket also spent over 10 years in Regulatory Affairs and R&D roles at CSL Limited. Her work led to the registration and maintenance of registration of CSL's plasma products in Australian and international markets, and the development and commercialisation of three immunodiagnostic kits for Human and Veterinary use.

Nuket holds a Bachelor of Science (Honours) from La Trobe University and a Master of Business Administration (MBA) from Monash University.

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (0)3 9827 8999

About Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). ATL1103 drug designed to block GHr production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly. The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients at the Royal Childrens Hospital, Melbourne.